Network origin in Piet Tom Wigerinck first degree
Entity | Entity type | Industry | |
---|---|---|---|
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.
4
| Subsidiary | Biotechnology | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Piet Tom Wigerinck via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
GALAPAGOS NV | Biotechnology | Founder President General Counsel | |
Nyenrode Business Universiteit | College/University | Undergraduate Degree | |
Mogen International Nv
Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Pharmaceuticals: Other | Corporate Officer/Principal | |
Molecular Probes, Inc.
Molecular Probes, Inc. BiotechnologyHealth Technology Molecular Probes, Inc. has manufactured fluorescence-based detection solutions for use in labeling molecules for biological research and drug discovery. The company was headquartered in Eugeme, OR. | Biotechnology | Corporate Officer/Principal | |
INSEAD | College/University | Masters Business Admin | |
Wageningen University | College/University | Graduate Degree | |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Molecular Probes Europe BV | Corporate Officer/Principal | ||
Netherlands Foreign Investment Agency
Netherlands Foreign Investment Agency Financial ConglomeratesFinance The Netherlands Foreign Investment Agency provides business investment services. The private company is based in San Francisco, CA and has subsidiaries in the Netherlands. | Financial Conglomerates | Corporate Officer/Principal | |
Sanofi European Treasury Center SA
Sanofi European Treasury Center SA Financial ConglomeratesFinance Part of Sanofi, Sanofi European Treasury Center SA provides financial services. The company is based in Brussels, Belgium. | Financial Conglomerates | Director of Finance/CFO | |
PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Institute For Human Organ & Disease Model Technologies | Director/Board Member | ||
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Pharmaceuticals: Major | Director/Board Member | |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
Netherlands | 11 |
Belgium | 4 |
United States | 3 |
Switzerland | 3 |
France | 2 |
Sectoral
Health Technology | 9 |
Consumer Services | 4 |
Finance | 4 |
Commercial Services | 2 |
Operational
Director/Board Member | 12 |
Corporate Officer/Principal | 6 |
Independent Dir/Board Member | 3 |
Director of Finance/CFO | 3 |
Chief Executive Officer | 2 |
Most connected contacts
- Stock Market
- Insiders
- Piet Tom Wigerinck
- Company connections